15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $129M | -$39M | 31.3% | -13.4% | -$14M | $130M | $8M |
| 2024 | $128M | $12M | 32.6% | -6.9% | -$18M | $125M | $8M |
| 2023 | $103M | -$100M | 27.1% | -21.1% | — | $85M | $19M |
| 2022 | $111M | -$117M | 35.1% | -10.6% | -$49M | $98M | $991000 |
| 2021 | $101M | -$32M | 38.6% | -8.7% | -$3M | $165M | $763000 |
| 2020 | $160M | -$38M | 24.6% | -16.2% | -$29M | $113M | $360000 |
| 2019 | $558M | $411000 | 14.5% | 1.0% | -$29M | $97M | $1M |
| 2018 | $524M | $25M | 14.9% | 2.6% | -$14M | $42M | $3M |
| 2017 | $470M | $11M | 16.9% | 3.1% | $7M | $47M | $6M |
| 2016 | — | -$12M | — | — | -$19M | $54M | $10M |
| 2015 | — | $14M | — | — | — | $43M | $14M |
| 2014 | — | $19M | — | — | — | $34M | $14M |
| 2013 | — | $23M | — | — | $12M | $40M | $14M |
| 2012 | — | $13M | — | — | $17M | $47M | $22M |
| 2011 | — | $4M | — | — | $8M | $20M | $8M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $23M | -$15M | 19.2% | -20.1% | $4M | $149M | $21M |
| Sep '25 | $31M | -$10M | 25.0% | -9.9% | $25000 | $136M | $19M |
| May '25 | $36M | -$1M | 38.4% | 14.6% | $3M | $130M | $8M |
| Feb '25 | $35M | -$15M | 28.0% | -25.7% | -$4M | $125M | $5M |
| Nov '24 | $33M | -$7M | 34.0% | -6.0% | -$9M | $111M | $9M |
| Aug '24 | $25M | -$16M | 21.8% | -46.9% | -$4M | $106M | — |
| May '24 | $38M | -$7M | 45.6% | 5.7% | $6M | $125M | $8M |
| Feb '24 | $36M | $16M | 33.3% | -2.5% | -$8M | $97M | — |
| Nov '23 | $30M | $14M | 33.0% | -4.9% | -$3M | $93M | — |
| Aug '23 | $25M | -$11M | 11.1% | -35.1% | -$13M | $89M | — |
| May '23 | $31M | -$39M | 25.0% | -21.3% | — | $85M | $19M |
| Feb '23 | $27M | -$37M | 32.2% | -24.6% | -$19M | $99M | $3M |
| Nov '22 | $22M | -$13M | 26.0% | -24.5% | -$6M | $99M | $6M |
| Aug '22 | $24M | -$11M | 25.2% | -13.8% | -$4M | $99M | $3M |
| May '22 | $28M | -$56M | 37.1% | -8.9% | -$8M | $98M | $991000 |
| Feb '22 | $35M | -$14M | 33.0% | -27.4% | -$23M | $80M | $1M |
| Nov '21 | $26M | -$38M | 44.8% | 14.4% | -$11M | $124M | $609000 |
| Aug '21 | $22M | -$9M | 24.8% | -18.9% | -$7M | $124M | $939000 |
| May '21 | $45M | -$1M | 32.5% | 4.6% | -$3M | $165M | $763000 |
| Feb '21 | $28M | -$7M | 39.3% | 0.3% | -$12M | $145M | $2M |
How the market has priced LFCR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, LIFECORE BIOMEDICAL, INC. \DE\'s revenue has declined 4.2% per year. These are computed facts, not advice.
As of FY2025, LIFECORE BIOMEDICAL, INC. \DE\ reported $130M of total debt against $8M of cash.
In FY2025, gross margin was 31.3%, operating margin -13.4%, and net margin -30.0%.
As of Jun '26, LIFECORE BIOMEDICAL, INC. \DE\ traded at a price-to-earnings ratio of about 21.1× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.